文献速递心力衰竭与心肌病

循环microRNA联合NT-proBNP检测与分类心力衰竭亚型

Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究在来自新加坡和新西兰的1710例受试者(903例心衰、807例非心衰)中推导并验证循环microRNA特征用于非急性心衰的识别。8-microRNA panel联合NT-proBNP显著提高了特异度和准确度,尤其在射血分数保留的心衰(HFpEF)中可纠正NT-proBNP漏诊。

要点

  • 8-microRNA panel联合NT-proBNP在发现队列中AUC达0.99,特异度0.99,准确度0.93。
  • 联合标志物可正确重分类多数NT-proBNP漏诊的HFpEF病例(新加坡72%,新西兰88%)。
  • 联合标志物区分HFpEF与HFrEF的效能中等(AUC 0.65–0.81),需进一步优化。

核心结论

  • 多microRNA panel联合NT-proBNP对非急性心衰具有高度判别力,并提高特异度和准确度。
  • 联合标志物在NT-proBNP不确定时(尤其HFpEF)有潜在识别价值。

研究设计与样本

  • 研究纳入来自新加坡和新西兰的发现与验证队列共1710例(903例心衰,807例非心衰)。
  • microRNA panel在新加坡发现队列(n=546)中建立,并在新加坡验证1队列(n=448)和新西兰验证2队列(n=716)中独立验证。

主要发现

  • 发现队列中8-microRNA panel识别心衰的AUC为0.96,特异度0.88,准确度0.89;验证1对应为0.88、0.66、0.77;验证2为0.87、0.58、0.74。
  • 联合microRNA panel与NT-proBNP后,发现队列AUC从NT-proBNP单用的0.96提升至0.99,特异度从0.91提升至0.99,准确度从0.90提升至0.93;验证1对应为0.97、0.96、0.93。
  • 8-microRNA发现panel区分HFpEF与HFrEF的AUC为0.81,特异度0.66,准确度0.72;验证1为0.65、0.41、0.56;验证2为0.65、0.41、0.62。
  • 联合标志物用于表型分类在发现队列AUC 0.87、特异度0.75、准确度0.77;验证1为0.74、0.59、0.67;验证2为0.72、0.52、0.68;NT-proBNP单用发现队列AUC 0.71、特异度0.46、准确度0.62;验证1为0.72、0.44、0.57;验证2为0.69、0.48、0.66。
  • 按指南推荐的NT-proBNP排除阈值判定的假阴性病例(新加坡81%和所有新西兰假阴性均为HFpEF)中,8-microRNA panel正确重分类了多数(新加坡72%,新西兰88%)。

临床怎么用

  • 在临床评估、影像和NT-proBNP无法明确非急性心衰时,可考虑联合microRNA panel与NT-proBNP提高识别准确性。
  • 对NT-proBNP排除阈值以下但疑似HFpEF的患者,microRNA panel可能辅助纠正漏诊。

局限性

  • 区分HFpEF与HFrEF的效能中等,验证队列中特异度较低(0.41–0.66)。
  • 研究队列来自新加坡和新西兰,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinicians need improved tools to better identify nonacute heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: The purpose of this study was to derive and validate circulating microRNA signatures for nonacute heart failure (HF). METHODS: Discovery and validation cohorts (N = 1,710), comprised 903 HF and 807 non-HF patients from Singapore and New Zealand (NZ). MicroRNA biomarker panel discovery in a Singapore cohort (n = 546) was independently validated in a second Singapore cohort (Validation 1; n = 448) and a NZ cohort (Validation 2; n = 716). RESULTS: In discovery, an 8-microRNA panel identified HF with an area under the curve (AUC) 0.96, specificity 0.88, and accuracy 0.89. Corresponding metrics were 0.88, 0.66, and 0.77 in Validation 1, and 0.87, 0.58, and 0.74 in Validation 2. Combining microRNA panels with N-terminal pro-B-type natriuretic peptide (NT-proBNP) clearly improved specificity and accuracy from AUC 0.96, specificity 0.91, and accuracy 0.90 for NT-proBNP alone to corresponding metrics of 0.99, 0.99, and 0.93 in the discovery and 0.97, 0.96, and 0.93 in Validation 1. The 8-microRNA discovery panel distinguished HFpEF from HF with reduced ejection fraction with AUC 0.81, specificity 0.66, and accuracy 0.72. Corresponding metrics were 0.65, 0.41, and 0.56 in Validation 1 and 0.65, 0.41, and 0.62 in Validation 2. For phenotype categorization, combined markers achieved AUC 0.87, specificity 0.75, and accuracy 0.77 in the discovery with corresponding metrics of 0.74, 0.59, and 0.67 in Validation 1 and 0.72, 0.52, and 0.68 in Validation 2, as compared with NT-proBNP alone of AUC 0.71, specificity 0.46, and accuracy 0.62 in the discovery; with corresponding metrics of 0.72, 0.44, and 0.57 in Validation 1 and 0.69, 0.48, and 0.66 in Validation 2. Accordingly, false negative (FN) (81% Singapore and all NZ FN cases were HFpEF) as classified by a guideline-endorsed NT-proBNP ruleout threshold, were correctly reclassified by the 8-microRNA panel in the majority (72% and 88% of FN in Singapore and NZ, respectively) of cases. CONCLUSIONS: Multi-microRNA panels in combination with NT-proBNP are highly discriminatory and improved specificity and accuracy in identifying nonacute HF. These findings suggest potential utility in the identification of nonacute HF, where clinical assessment, imaging, and NT-proBNP may not be definitive, especially in HFpEF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Wong LL, Zou R, Zhou L, et al. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. J Am Coll Cardiol. 2019. PMID: 30898206. doi:10.1016/j.jacc.2018.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。